丽珠医药集团股份有限公司 第十一届监事会第十五次会议公告 本公司及监事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-063 特此公告。 丽珠医药集团股份有限公司监事会 丽珠医药集团股份有限公司（以下简称"公司"）第十一届监事会第十五次会 议于2025年10月23日以现场和通讯表决相结合的方式召开，会议通知已于2025 年 10 月 10 日以电子邮件形式发送，现场会议地址为珠海市金湾区创业北路 38 号丽珠工业园总部大楼 9 楼会议室，本次会议应参会监事 3 人，实际参会监事 3 人，本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和公司章 程的规定，经与会监事认真审议，作出如下决议： 2025 年 10 月 24 日 一、审议通过《关于丽珠医药集团股份有限公司 2025 年第三季度报告的议 案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 二、审议通过《关于取消监事会、修订〈公司章程〉并办理工商变更登记的 议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-062 丽珠医药集团股份有限公司 第十一届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）第十一届董事会第二十七次 会议于 2025 年 10 月 23 日以现场和通讯表决相结合的方式召开，会议通知已于 2025 年 10 月 9 日以电子邮件形式发送，现场会议地址为珠海市金湾区创业北路 38 号丽珠工业园总部大楼 9 楼会议室，本次会议应参会董事 11 人，实际参会董 事 11 人，本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，经与会董事认真审议，作出如下决议： 一、审议通过《丽珠医药集团股份有限公司 2025 年第三季度报告》 《关于取消监事会、修订〈公司章程〉并办理工商变更登记的公告》及修订 后的《丽珠医药集团股份有限公司章程（待提交股东大会审议）》已于本公告日 披露于《中国证券报》《证券时报》《证券日报》《上海证券报》及巨潮资讯网 （www.cninfo.com.c ...

智通财经APP讯，丽珠医药(01513)发布2025年前三季度业绩，该集团取得营业收入91.16亿元，同比增 加0.38%;归属于公司股东的净利润17.54亿元，同比增加4.86%;基本每股收益1.96元。 ...

丽珠医药集团股份有限公司 2025 年第三季度报告 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-065 丽珠医药集团股份有限公司 2025 年第三季度报告 2025 年 10 月 1 丽珠医药集团股份有限公司 2025 年第三季度报告 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.丽珠医药集团股份有限公司（以下简称"本公司"或"公司"）董事会、监事会及董事、监事、高级管理人员保证公司 2025 年第三季度报告（以下简称"本季度报告"）的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别 和连带的法律责任。 2.公司负责人朱保国先生、主管会计工作负责人及会计机构负责人（会计主管人员）司燕霞女士声明：保证本季度报告中 财务信息的真实、准确、完整。 3.本季度报告分别以中文及英文编订，如对中英文文本的理解发生歧义时，概以中文文本为准。本季度报告所附财务报表 及相应资料均按照中国《企业会计准则》编制，除非另有说明，货币单位均为人民币。 4.第三季度报告是否经过审计 ...

格隆汇10月23日丨丽珠医药(01513.HK)发布公告，2025年第三季度，实现营业收入28.44亿元(人民币， 下同)，同比增长1.60%；归属于上市公司股东的净利润4.73亿元，同比下降5.73%；归属于上市公司股 东的扣除非经常性损益的净利润4.54亿元，同比下降4.58%；基本每股收益0.52元。 ...

Financial Performance - Total revenue for Q3 2025 reached RMB 2,844,001,646.29, an increase of 1.60% compared to the same period last year[6] - Net profit attributable to shareholders decreased by 5.73% to RMB 473,012,359.77 for Q3 2025[6] - Basic earnings per share for Q3 2025 was RMB 0.52, down 3.70% year-on-year[6] - For the first nine months of 2025, the company reported operating revenue of RMB 9,115,914,290.40, a slight increase from RMB 9,081,603,788.36 in the same period of 2024, representing a growth of approximately 0.38%[28] - The operating profit for the same period was RMB 2,510,927,913.36, compared to RMB 2,315,421,100.65 in 2024, indicating an increase of about 8.44%[28] - The net profit attributable to shareholders of the parent company for the first nine months of 2025 was RMB 1,754,100,316.30, up from RMB 1,672,733,989.63 in 2024, reflecting a growth of approximately 4.86%[28] - Total comprehensive income for the period (January to September 2025) reached RMB 2,071,231,848.52, an increase from RMB 1,896,000,641.95 in the same period of 2024, representing a growth of approximately 9.2%[29] - Basic and diluted earnings per share for the period were both RMB 1.96, up from RMB 1.81 in the same period last year, representing an increase of about 8.3%[29] Assets and Liabilities - Total assets as of the end of Q3 2025 amounted to RMB 24,537,984,410.75, reflecting a 0.34% increase from the previous year[8] - Total assets as of September 30, 2025, amounted to RMB 24,537,984,410.75, slightly up from RMB 24,455,825,697.18 at the beginning of the year[26] - Current assets totaled RMB 16,572,128,734.92, compared to RMB 16,419,980,644.30 at the start of the year, showing an increase of about 0.92%[26] - Total liabilities decreased to RMB 9,170,977,356.02 from RMB 9,550,079,103.14, a reduction of approximately 3.96%[27] - The company’s total equity attributable to shareholders increased by 0.73% to RMB 13,962,841,806.50[8] - The company’s total equity attributable to shareholders increased to RMB 13,962,841,806.50 from RMB 13,862,334,189.33, reflecting a growth of about 0.72%[27] Cash Flow - Cash flow from operating activities for the year-to-date period increased by 9.42% to RMB 2,525,421,252.84[6] - Net cash flow from operating activities for the period was RMB 2,525,421,252.84, compared to RMB 2,307,915,362.28 in the previous year, indicating an increase of about 9.5%[30] - Cash inflow from investment activities skyrocketed by 993.72% to 4,935,250,581.28 RMB, primarily from the maturity of structured deposits[16] - Cash outflow from investment activities increased by 508.37% to 6,561,574,810.45 RMB, mainly due to new structured deposits[16] - The net cash flow from investment activities was -1,626,324,229.17 RMB, a decrease of 159.25% compared to the previous period[16] - Net cash flow from financing activities showed a decrease, with a net outflow of RMB 1,750,752,190.63 compared to RMB 1,912,251,596.10 in the previous year, reflecting a reduction of approximately 8.4%[31] Expenses and Investments - Development expenses rose by 61.40% to RMB 355,884,300.38, mainly due to increased investment in clinical trials for the JP1366 tablet[14] - Financial expenses increased by 244.07% to -189,000,313.28 RMB due to higher interest income from deposits[15] - Investment income rose by 88.08% to 48,706,390.01 RMB, primarily from changes in the profit and loss of associated companies[15] - Fair value changes in investment income improved by 144.49% to 2,447,091.77 RMB, reflecting fluctuations in the market value of held securities[15] - Credit impairment losses surged by 2317.48% to -7,890,079.59 RMB, mainly due to increased expected credit losses on receivables[15] - Research and development expenses for the first nine months of 2025 were RMB 683,264,467.54, compared to RMB 734,493,897.75 in 2024, indicating a decrease of approximately 6.96%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period was 47,362, with 47,343 being A-share shareholders[19] - The company repurchased a total of 15,376,845 A-shares, accounting for 1.70% of the total share capital, with a total expenditure of 570,228,471.25 RMB[24] - As of September 30, 2025, the company has not repurchased any H-shares[25] Cash and Cash Equivalents - The company’s cash and cash equivalents were RMB 9,918,953,931.89, down from RMB 10,827,146,984.92 at the beginning of the year, a decrease of about 8.39%[26] - The total cash and cash equivalents at the end of the period stood at RMB 9,909,534,008.29, down from RMB 10,723,355,139.50 at the end of the previous year, a decrease of approximately 7.6%[31] - Cash received from sales of goods and services was RMB 9,744,458,934.54, slightly down from RMB 9,877,413,424.19 in the previous year, a decrease of about 1.3%[30] - The company received RMB 28,799,064.00 from investments during the period, a decrease from RMB 161,751,999.95 in the previous year, reflecting a decline of approximately 82.2%[31] - The impact of exchange rate changes on cash and cash equivalents was a decrease of RMB 56,627,486.05, compared to a decrease of RMB 21,353,488.46 in the previous year, indicating a worsening of approximately 165.7%[31]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 取消監事會、修訂〈公司章程〉 並辦理工商變更登記 2025年10月23日，麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.* （「本公司」）召開了第十一屆董事會（「董事会」）第二十七次會議，審議通過了 《關於取消監事會、修訂〈公司章程〉並辦理工商變更登記的議案》《關於修訂〈股 東大會議事規則〉並更名的議案》及《關於修訂〈董事會議事規則〉的議案》等議案。 現將有關詳情公告如下： 一、取消監事會的相關情況 – 2 – （一）《公司章程》主要修訂前後對照表如下： | 現行條款 | 修訂後條款 | | --- | --- | | 第一條 為維護麗珠醫藥集團股份有限公司（以下 | 第一條 為維護麗珠醫藥集團股份有限公司（以下 | | 簡稱公司）、股東和債權人的合法權益，規範公司 | 簡稱公司）、股東、職工和債權人的合法權益，規 | | 的組織和行為，根據《中華人民共和國公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司第十一屆監事會第十五次會議公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 劉寧 中國，珠海 二零二五年十月二十三日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 * 僅供識別 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 丽珠医药集团股份有限公司（以下简称"公司"）第十一届监事会第十五次会 议于2025年10月23日以现场和通讯表决相结合 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司第十一屆董事會第二十七次會議決議公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 劉寧 中國，珠海 二零二五年十月二十三日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 * 僅供識別 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-062 丽珠医药集团股份有 ...

Core Viewpoint - The news provides an overview of the upcoming IPOs, earnings announcements, shareholder meetings, and dividend distributions for various companies listed on the Hong Kong Stock Exchange as of October 23, 2025 [1]. New IPO Activities - Companies currently in the IPO process include: - Baima Tea Industry - Cambridge Technology - Sany Heavy Industry - Dipu Technology - Prada - Lijuz Pharmaceutical [1] Earnings Announcement Dates - Companies scheduled to announce earnings include: - Faraday - Ping An Good Doctor - Longyuan Power - Orient Overseas International - Qingdao Port - China Innovation Investment - Chongqing Machinery and Electric [1] Shareholder Meeting Dates - Companies holding shareholder meetings include: - Datang Power - Andeli Juice - Hongye Futures - Tibet Water Resources - China Anshun Energy [1] Dividend Distribution - Companies with upcoming dividend distributions include: - Hang Seng Bank (ex-dividend date) - Huaxun (dividend payment date) - Wansichang International (dividend payment date) - Zhifeng Industrial Electronics (dividend payment date) - Haitian Flavoring and Food (dividend payment date) - China Shipbuilding Defense (dividend payment date) - Dongfang Xingye Holdings (dividend payment date) - China Resources Mixc Life (dividend payment date) [1][3][4]